ATH 33.3% 0.4¢ alterity therapeutics limited

Ann: Notice Under Section 708A, page-18

  1. 400 Posts.
    lightbulb Created with Sketch. 150
    Hi Lectriod,
    It's funny you should mention NEU. A very close friend of mine told me about NEU years ago when the SP was languishing under a cent. Every time we used to see each other, he would constantly harp on about buying shares in it. It got to the point where he was almost on his hands and knees begging me to buy shares. To my own detriment, I didn't listen. To this day, he is still a massive shareholder of NEU and credit to him, as he has done extremely well. The old adage "You can lead a horse to water but can't make it drink" fits perfectly in this situation. My dear friend is somewhat classified as a technical investor. His decision to invest in any Bio-Med Companies solely depends on the science of what each company is trying to achieve. If success were to be measured purely by financial gain, then this fellow is most definitely at the head of the class.
    Which now leads us back to our little Alterity Therapeutics. My friend is now here at ATH and is excited about the science. When the Primate Study results were released late last year, this fellow couldn't contain his enthusiasm for what Alterity had achieved. Although it was achieved in primates and not humans, he was still thrilled by the fact that ATH has identified that moving excess iron to different parts of the brain would would improve current symptoms faced by MSA suffers. Another point in case is the Bio Markers being used in the current study. By using bio markers in the current trials, it gives scientists a more accurate reading of any minor improvements that may be achieved by our patients. This point is very important to note; as I believe this wasn't done in previous trials.
    The other major difference between NEU and ATH way back when is, NEU still had a very long road ahead. It's now been a good 8 years since I had first heard about NEU. With ATH, it's at the same price point, except we don't have to wait 8 years. It's in the here and now. If it's going to pay off, it will pay off this year. If Stamler and Crew get it right, it will bear fruit in the very near team. If not, then we are doomed, and "it is what it is." Im personally hoping we all come out the other side spitting chips we didn't buy more! That would be the optimal outcome. As always, this is only my opinion and GLTAHs.
    Last edited by Stockman: 10/03/24
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.